Almut Grenz1, Eric Clambey, Holger K Eltzschig. 1. Mucosal Inflammation Program, Department of Anesthesiology, University of Colorado, Aurora, Colorado 80045, USA. almut.grenz@ucdenver.edu
Abstract
PURPOSE OF REVIEW: During critical illness, alterations of intestinal blood supply and inflammatory activation can result in severe intestinal hypoxia (limited oxygen availability). Conditions of hypoxia lead to the activation of a transcriptional program that is under the control of the transcription factor hypoxia-inducible factor (HIF). In many instances, HIF-dependent alterations of gene expression represent endogenous adaptive responses that dampen pathologic inflammation and could be targeted to treat intestinal injury. RECENT FINDINGS: Post-translational stabilization of the HIF transcription factor and corresponding changes in gene expression are central to the resolution of intestinal injury. Examples for such responses that we discuss in this review include hypoxia-elicited increases in extracellular adenosine production and signaling, particularly through the A2B adenosine receptor, and intestinal protection provided by hypoxia-inducible netrin-1. SUMMARY: The present review focuses on HIF-elicited anti-inflammatory pathways that result in intestinal protection during critical illness. Many of these pathways represent novel therapeutic targets for attenuating multiorgan failure and critical illness. Whereas these therapeutic approaches are currently being investigated in cell culture models or in genetic mouse models, we are optimistic that at least some of these novel targets can be translated from bench to bedside in the near future.
PURPOSE OF REVIEW: During critical illness, alterations of intestinal blood supply and inflammatory activation can result in severe intestinal hypoxia (limited oxygen availability). Conditions of hypoxia lead to the activation of a transcriptional program that is under the control of the transcription factor hypoxia-inducible factor (HIF). In many instances, HIF-dependent alterations of gene expression represent endogenous adaptive responses that dampen pathologic inflammation and could be targeted to treat intestinal injury. RECENT FINDINGS: Post-translational stabilization of the HIF transcription factor and corresponding changes in gene expression are central to the resolution of intestinal injury. Examples for such responses that we discuss in this review include hypoxia-elicited increases in extracellular adenosine production and signaling, particularly through the A2Badenosine receptor, and intestinal protection provided by hypoxia-inducible netrin-1. SUMMARY: The present review focuses on HIF-elicited anti-inflammatory pathways that result in intestinal protection during critical illness. Many of these pathways represent novel therapeutic targets for attenuating multiorgan failure and critical illness. Whereas these therapeutic approaches are currently being investigated in cell culture models or in genetic mouse models, we are optimistic that at least some of these novel targets can be translated from bench to bedside in the near future.
Authors: Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia Journal: Nat Med Date: 2010-12-19 Impact factor: 53.440
Authors: Ann-Kathrin Riegel; Marion Faigle; Stephanie Zug; Peter Rosenberger; Bernard Robaye; Jean-Marie Boeynaems; Marco Idzko; Holger K Eltzschig Journal: Blood Date: 2010-12-20 Impact factor: 22.113
Authors: Holger K Eltzschig; Parween Abdulla; Edgar Hoffman; Kathryn E Hamilton; Dionne Daniels; Caroline Schönfeld; Michaela Löffler; German Reyes; Michael Duszenko; Jorn Karhausen; Andreas Robinson; Karen A Westerman; Imogen R Coe; Sean P Colgan Journal: J Exp Med Date: 2005-12-05 Impact factor: 14.307
Authors: Stefan F Ehrentraut; Douglas J Kominsky; Louise E Glover; Eric L Campbell; Caleb J Kelly; Brittelle E Bowers; Amanda J Bayless; Sean P Colgan Journal: J Immunol Date: 2012-12-03 Impact factor: 5.422
Authors: Michael A Zimmerman; Almut Grenz; Eunyoung Tak; Maria Kaplan; Douglas Ridyard; Kelley S Brodsky; Mercedes Susan Mandell; Igal Kam; Holger K Eltzschig Journal: Proc Natl Acad Sci U S A Date: 2013-06-28 Impact factor: 11.205
Authors: Maria Nikiforou; Carolin Willburger; Anja E de Jong; Nico Kloosterboer; Reint K Jellema; Daan R M G Ophelders; Harry W M Steinbusch; Boris W Kramer; Tim Wolfs Journal: Mol Med Date: 2016-04-14 Impact factor: 6.354
Authors: Aránzazu Mediero; Bhama Ramkhelawon; Tuere Wilder; P Edward Purdue; Steven R Goldring; M Zahidunnabi Dewan; Cynthia Loomis; Kathryn J Moore; Bruce N Cronstein Journal: Ann Rheum Dis Date: 2015-10-09 Impact factor: 19.103
Authors: Eunyoung Tak; Douglas Ridyard; Alexander Badulak; Antasia Giebler; Uladzimir Shabeka; Tilmann Werner; Eric Clambey; Radu Moldovan; Michael A Zimmerman; Holger K Eltzschig; Almut Grenz Journal: J Mol Med (Berl) Date: 2013-05-01 Impact factor: 4.599